Deregulation of the protein kinase C (PKC) signalling pathway has been implicated in tumor
progression. Here we investigated the PKC inhibitor enzastaurin for its activity against …

Leukemia is a malignant clonal disease of hematopoietic stem cells, which accounts for
about 3% of the total incidence of tumors and is particularly prevalent among children and …

Constitutively activated AKT kinase is a common feature of T-cell acute lymphoblastic
leukemia (T-ALL). Here, we report that the novel AKT inhibitor (2 S)-1-(1 H-indol-3-yl)-3-[5-(3 …

Paediatric acute myeloid leukaemia (AML) continues to present treatment challenges, as no
“standard approach” exists to treat those young patients reliably and safely. Combination …

Leukemia stem cells (LSCs) account for the development of drug resistance and increased
recurrence rate in acute myeloid leukemia (AML) patients. Targeted drug delivery to …

Although great efforts have been made to improve available therapies, the mortality rate of
acute myeloid leukemia (AML) remains high due to poor treatment response and frequent …

Protein kinase B (PKB or Akt) is a central component of the PI3K-PKB-mTOR signalling
cascade and is firmly established as an attractive target for pharmacological intervention in …

mTORC1 inhibitors, including rapamycin and its analogs, have been actively studied both
pre-clinically and clinically. However, the single treatment of mTORC1 inhibitors has been …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant disorder arising
within the thymus from the clonal proliferation of T-cell precursors. T-ALL accounts for 25 …

Achieving a cure for high-risk neuroblastoma, the most common extracranial solid tumor in
children, remains a formidable task despite the recent addition of antibody-mediated anti …